Scarica l'app Stockscreener
25.16
2.07%
0.51
Pre-mercato:
25.18
0.02
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Stock Analysis | Pfizer OutlookA Weak Technical Picture Amid Mixed Analyst Signals - AInvest
FDA may revoke Pfizer COVID-19 shot for young, healthy children. - Yahoo News Canada
FDA could make it harder to get young kids a COVID shot - The Hill
Not for Granted: Pediatric Immunization Through Experts’ Lens - Pfizer
Pfizer Stock Is Making Moves On Promising Cancer Data. It Is Now A Buy? - Investor's Business Daily
Pfizer (PFE) Reports Promising Phase 3 Results For Bladder Cancer Treatment Combination - simplywall.st
Why is Pfizer Inc. stock going upMarket Movers & Weekly Breakout Stock Alerts - 선데이타임즈
Pfizer says FDA may pull its Covid vaccine for young children - Endpoints News
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer’s Rimegepant Study: A New Hope for Migraine Prevention in Japan - TipRanks
Pfizer’s Latest Study on HER2-positive Breast Cancer: Key Insights for Investors - TipRanks
Pfizer’s New Cancer Study: A Potential Game Changer? - TipRanks
FDA may pull authorization for Pfizer COVID shot for kids under 5 - The Hill
Pfizer’s Zavegepant Study: A New Hope for Migraine Relief in Asia - TipRanks
Should You Now Consider Selling Your Pfizer (PFE) Shares Before its Too Late? - Yahoo Finance
Cantor Fitzgerald maintains Neutral rating on Pfizer stock at $24 price target - Investing.com
FDA may revoke Pfizer COVID-19 vaccine authorization for kids under certain age - Fox Business
Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB - Yahoo Finance
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer - Yahoo Finance
The Top 5 Analyst Questions From Pfizer’s Q2 Earnings Call - Yahoo Finance
[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Pfizer Stock Surges on Revised Earnings Guidance as $850M Trading Volume Ranks 117th Amid Valuation Discount to Peers - AInvest
Pfizer/BioNTech may not win FDA renewal for pediatric COVID shot: report - MSN
Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study - insights.citeline.com
FDA may pull authorization of Pfizer's Covid vaccine for children under 5, company says - CNBC
Pfizer (PFE) Reports Positive Phase 3 Results In Bladder Cancer Treatment Study - simplywall.st
Pfizer Raises Its Guidance And Analysts Up Their TargetsPFE Stock Looks Cheap - Barchart.com
The Zacks Analyst Blog Highlights Pfizer, Novo Nordisk and Eli Lilly - The Globe and Mail
Pfizer looks to expand ADC use after positive bladder cancer data - BioPharma Dive
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: Key Insights for Investors - TipRanks
Pfizer and Astellas Pharma’s Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer’s Abrocitinib Study: A Potential Game-Changer for Atopic Dermatitis Treatment - TipRanks
Pfizer’s MagnetisMM-4 Study: A New Hope for Multiple Myeloma Treatment - TipRanks
Pfizer In Spotlight As FDA Reportedly Mulls Withdrawing Authorization For COVID-19 Vaccine For Kids Under 5 - Stocktwits
What's Going On With Merck Stock Tuesday?Merck & Co (NYSE:MRK), Pfizer (NYSE:PFE) - Benzinga
BlinkRx’s Ties to Donald Trump Jr. Questioned Amid Pfizer and Elicio Therapeutics’ Cancer Research Updates - geneonline.com
Former Pfizer Chief Scientific Officer joins MC Sciences as Independent Chairman - Yahoo Finance
Implications of Potential Pfizer Pediatric Vaccine Withdrawal on the U.S. Immunization Market - AInvest
Ascites Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company - The Globe and Mail
Pfizer's combination therapy improves survival in bladder cancer trial - Reuters
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business - simplywall.st
Statutory Profit Doesn't Reflect How Good Pfizer's (NYSE:PFE) Earnings Are - Yahoo Finance
FDA Weighs Pulling Pfizer’s Covid Vaccine for Kids Under Age 5 - Bloomberg.com
Pfizer’s combination therapy improves survival in bladder cancer trial - PharmaLive
Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer - Seeking Alpha
Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda - Yahoo Finance
Pfizer and Merck's Bladder Cancer Breakthrough: A Paradigm Shift in Oncology and a Win for Shareholders? - AInvest
Pfizer-Astellas bladder cancer therapy shows survival benefits in trial By Investing.com - Investing.com South Africa
Pfizer and Astellas Announce Breakthrough in Bladder Cancer Treatment - TipRanks
Pfizer drug extends survival for some bladder cancer patients | STAT - statnews.com
Pfizer’s Padcev Plus Keytruda Extends Bladder Cancer Survival - Bloomberg.com
Eli Lilly, Pfizer Seek Spot in China Private Insurance Catalog - Bloomberg.com
Pfizer Just Beat Its Earning Estimates. Is This the Beginning of a Turnaround for the Pharmaceutical Stock? - Yahoo Finance
If You'd Invested $1,000 in Pfizer (PFE) Stock 3 Years Ago, Here's How Much You'd Have Today - Yahoo Finance
Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI™ In Hemophilia A or B With Inhibitors - Insider Monkey
Astrocytoma Market to See Strong Growth Through 2034 as Pfizer, - openPR.com
Pfizer workers taken to hospital for 'potential exposure to materials,' company says - WWMT
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply - Benzinga
Sponsored Content: Pfizer’s Anti-Counterfeit Lab - WTNH.com
Pfizer’s New Study on Zavicefta: A Potential Game-Changer for Sepsis and Renal Impairment - TipRanks
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: Key Update for Investors - TipRanks
Flu Shot Season Puts Pfizer Back In Radio’s Ad Elite - Radio Ink
Pfizer launches next-gen vaccine for pneumococcal disease - The Economic Times
Should Pfizer Stock Be in Your Portfolio After Solid Q2 Results? - The Globe and Mail
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):